Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Landgren, C. Ola, Chari, Ajai, Cohen, Yael C., Spencer, Andrew, Voorhees, Peter, Estell, Jane A., Sandhu, Irwindeep, Jenner, Matthew W., Williams, Catherine, Cavo, Michele, van de Donk, Niels W. C. J., Beksac, Meral, Moreau, Philippe, Goldschmidt, Hartmut, Kuppens, Steven, Bandekar, Rajesh, Clemens, Pamela L., Neff, Tobias, Heuck, Christoph, Qi, Ming, Hofmeister, Craig C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326703/
https://www.ncbi.nlm.nih.gov/pubmed/32024950
http://dx.doi.org/10.1038/s41375-020-0718-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326703/
https://www.ncbi.nlm.nih.gov/pubmed/32024950
http://dx.doi.org/10.1038/s41375-020-0718-z

Ejemplares similares